Developer of drugs for rare, rheumatic diseases plans to double R&D spending in 2021
Horizon Therapeutics says the financial results it will report next month will have exceeded its expectations for 2020 despite the challenges of COVID-19, thanks to its two best-selling drugs generating between them more than $1 billion in net sales. [Horizon Therapeutics]
Krystexxa, approved in 2010 to treat chronic gout in adults refractory to conventional therapy, racked up more than $400 million in net sales while Tepezza, the first and to date only therapy approved for treating thyroid eye disease, won approval in January 2020 and finished last year exceeding $800 million in net sales . . .
